Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

NOVARTIS AG : Goldman Sachs remains its Buy rating

11/25/2020 | 04:30am EST

In a research note, Goldman Sachs analyst Keyur Parekh has maintained his recommendation on the stock with a Buy rating. The target price is unchanged at CHF 109.


© MarketScreener with dpa-AFX Analyser 2020
Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG -0.60% 83.82 Delayed Quote.0.20%
THE GOLDMAN SACHS GROUP, INC. -2.99% 273.33 Delayed Quote.6.84%
All news about NOVARTIS AG
01/27NOVARTIS : DZ Bank Lifts Price Target on Novartis, Maintains Buy Recommendation
MT
01/27NOVARTIS : AlphaValue/Baader Europe Lifts Price Target on Novartis, Maintains Ad..
MT
01/27NOVARTIS AG : Credit Suisse reaffirms its Neutral rating
MD
01/27PRESS RELEASE : Just - Evotec Biologics Expands Contract with the Department of ..
DJ
01/27NOVARTIS : Eyes $4 Billion Sales in China By 2024
MT
01/27NOVARTIS : Places Second in 2021 Access to Medicine Index
MT
01/26Health Care Down After Mixed Earnings -- Health Care Roundup
DJ
01/26Wall Street Wavers Pre-Bell Amid Earnings Deluge
MT
01/26SECTOR UPDATE : Health Care Stocks Gain Pre-Bell Tuesday
MT
01/26US Futures Flat Ahead of Earnings Deluge
MT
More news
Financials (USD)
Sales 2020 49 122 M - -
Net income 2020 8 379 M - -
Net Debt 2020 20 219 M - -
P/E ratio 2020 25,7x
Yield 2020 3,37%
Capitalization 213 B 213 B -
EV / Sales 2020 4,74x
EV / Sales 2021 4,34x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 109,69 $
Last Close Price 94,24 $
Spread / Highest target 58,0%
Spread / Average Target 16,4%
Spread / Lowest Target -4,50%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG0.20%212 810
JOHNSON & JOHNSON6.67%448 796
ROCHE HOLDING AG4.51%312 213
PFIZER INC.-1.55%207 384
MERCK & CO., INC.-1.89%203 035
ELI LILLY AND COMPANY22.94%192 848